Kamada (KMDA) Gains As Market Dips: What You Should Know
Kamada (KMDA) closed at $6.13 in the latest trading session, marking a +0.02% move from the prior day. This change outpaced the S&P 500's 0.04% loss on the day. Elsewhere, the Dow lost 0.51%, while the tech-heavy Nasdaq added 0.21%.
Heading into today, shares of the biopharmaceutical had gained 5.35% over the past month, outpacing the Medical sector's loss of 5.37% and the S&P 500's gain of 4.65% in that time.
KMDA will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.05, up 66.67% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $22.87 million, up 31.14% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.47 per share and revenue of $126.91 million. These totals would mark changes of -17.54% and +10.87%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for KMDA. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. KMDA is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, KMDA is currently trading at a Forward P/E ratio of 13.07. Its industry sports an average Forward P/E of 20.82, so we one might conclude that KMDA is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 55, putting it in the top 22% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kamada Ltd. (KMDA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
